Glaukos jumps as Citi upgrades to Buy and raises target to $162
Glaukos shares rose about 3.35% to $126.35 as investors reacted to a bullish Wall Street upgrade and higher price target. The catalyst was Citi upgrading GKOS to Buy from Neutral and lifting its target to $162 from $132, highlighting improving fundamentals and a valuation reset.
1. What’s moving the stock today
Glaukos (GKOS) is trading higher today as the stock digests a fresh bullish analyst call. Citi upgraded the shares to Buy from Neutral and raised its price target to $162 from $132, pointing to a more constructive setup after a valuation reset and improving outlook for the company’s growth drivers. (tipranks.com)
2. Why the call matters for fundamentals
The upgrade lands with investors focused on two key revenue engines in 2026: iDose TR’s continued adoption in glaucoma and the commercialization path for Epioxa in corneal health. Glaukos has also been emphasizing 2026 net sales guidance of $600 million to $620 million and positioning the year as increasingly back-half weighted as access and reimbursement pathways develop for newer products. (investors.glaukos.com)
3. The bigger picture investors are trading
Beyond today’s upgrade, sentiment around Glaukos has been supported by regulatory progress that expands the iDose TR treatment playbook, including FDA approval of a labeling supplement enabling repeat-treatment labeling. That change is viewed as a demand and utilization tailwind because it can broaden the addressable treatment cycle and reduce uncertainty about long-term therapy continuity. (glance.eyesoneyecare.com)